Focus: Genomics is a UK-based biotechnology company specializing in human genetics platforms focused on rare diseases and genomic diagnostics. The company operates as a platform for genomic sequencing, molecular diagnostics, and biomarker discovery across oncology, rare genetic disorders, and transplant monitoring.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
Stable — net +3 jobs in 30d
3 added, 0 removed. Backfill posture.
Early-stage genomics platform with interesting science but significant data gaps and hiring stagnation; viable for specialists seeking ground-floor opportunity in precision medicine, but carries pre-revenue biotech risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Recently launched local anesthetic with extended exclusivity; peripheral to core genomics strategy and likely licensed asset.
Help build intelligence for Genomics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Genomics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: RAMBUS INC (RMBS) (CIK 0000917273) — 8-K
8-K
8-K Filing: Profusa, Inc. (PFSA, NVACW) (CIK 0001859807) — CURRENT REPORT
CURRENT REPORT
8-K Filing: FMC CORP (FMC) (CIK 0000037785) — EX-10.1
EX-10.1
Best Genomics Stocks for 2026 and How to Invest - The Motley Fool
Best Genomics Stocks for 2026 and How to Invest The Motley Fool
8-K Filing: Zentalis Pharmaceuticals, Inc. (ZNTL) (CIK 0001725160) — EX-99.2
EX-99.2
Chemotherapy treatment altered for patients following genomics testing scheme - pharmaceutical-journal.com
Chemotherapy treatment altered for patients following genomics testing scheme pharmaceutical-journal.com
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo